Fair value · BioNTech SE (BNTX) · updated 2026-11-18 · from 20-F FY2025
BioNTech trades at $83.00. That price implies a 2.9% free-cash-flow yield.
Cboe · delayed 15 min · as of 18:26 ET
Statements filed in EUR, converted to USD at the 2025-12-31 period-end rate (0.85106 EUR per USD; ECB reference rates).
Are those assumptions reasonable? Use BNTX’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- FCF yield
- 2.9%
free cash flow ÷ enterprise value (34.3× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 18:26 ET.
Inputs come from the FY2025 20-F filed (accession 0001776985-26-000017); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
BioNTech SE- Revenue
- EUR 2.9B
- Diluted EPS
- EUR -4.70
- Free cash flow
- EUR 280.9M
- operating cash flow − capital expenditure
- Diluted shares
- 241.7M
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-10 · accession 0001776985-26-000017
Open this filing on sec.govNeed BNTX data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.